Merck received approval from the U.S. FDA for an expanded indication for VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) to include children 6 weeks through 17 years of age.    VAXNEUVANCE is now indicated for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older. The approval follows the FDA’s Priority Review of Merck’s supplement...